KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Neogenomics (NEO) over the last 16 years, with Q4 2025 value amounting to $2.8 million.

  • Neogenomics' Treasury Shares rose 3075.34% to $2.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.8 million, marking a year-over-year increase of 3075.34%. This contributed to the annual value of $2.8 million for FY2025, which is 3075.34% up from last year.
  • Latest data reveals that Neogenomics reported Treasury Shares of $2.8 million as of Q4 2025, which was up 3075.34% from $3.0 million recorded in Q3 2025.
  • Over the past 5 years, Neogenomics' Treasury Shares peaked at $3.5 million during Q1 2025, and registered a low of $331982.0 during Q1 2021.
  • Its 5-year average for Treasury Shares is $1.9 million, with a median of $2.1 million in 2023.
  • In the last 5 years, Neogenomics' Treasury Shares plummeted by 1304.25% in 2021 and then surged by 30482.13% in 2022.
  • Neogenomics' Treasury Shares (Quarter) stood at $851403.0 in 2021, then surged by 134.3% to $2.0 million in 2022, then fell by 1.65% to $2.0 million in 2023, then grew by 10.3% to $2.2 million in 2024, then soared by 30.75% to $2.8 million in 2025.
  • Its Treasury Shares was $2.8 million in Q4 2025, compared to $3.0 million in Q3 2025 and $3.1 million in Q2 2025.